NSAIDs in the treatment and/or prevention of neurological disorders

被引：10
作者：
Parto S. Khansari
Leanne Coyne
机构：
[1] California Northstate College of Pharmacy, Rancho Cordova, CA 95670
来源：
Inflammopharmacology | 2012年 / 20卷 / 3期
关键词：
Alzheimer's disease; Amyotrophic lateral sclerosis; Aspirin; COX-2; Fenamates; Ibuprofen; Inflammation; Neuroprotection; Nimesulide; NSAIDs; Parkinson's disease; Stroke;
D O I：
10.1007/s10787-011-0116-2
中图分类号：
学科分类号：
摘要：
Non-steroidal anti-inflammatory drugs (NSA-IDs) have been used extensively in the treatment of inflammatory disorders and pain. In recent years, emerging data suggest that some NSAIDs possess pharmacological properties, in addition to cyclooxygenase inhibition, which may be beneficial in the treatment of several neurological conditions. For example, fenamate NSAIDs potentiate GABA-A receptor function, indomethacin scavenges nitric oxide free radicals, and acetylsalicylic acid inhibits the translocation of NF-κB, all of which may contribute to their neuroprotective actions in selected experimental models of stroke. The purpose of this review is to explore the diverse pharmacological properties of NSAIDs in relation to their potential value in the treatment of selected neurological diseases. © 2011 CARS.
引用
收藏
页码：159 / 167
页数：8
相关论文
共 90 条
  • [11] Botting R.M., Vane's discovery of the mechanism of action of aspirin changed our understanding of its clinical pharmacology, Pharmacol Rep, 62, 3, pp. 518-525, (2010)
  • [12] Breidert T., Callebert J., Heneka M.T., Landreth G., Launay J.M., Hirsch E.C., Protective action of the peroxisome proliferator-activated receptor gamma agonist pioglitazone in a mouse model of Parkinson's disease, J Neurochem, 82, 3, pp. 615-624, (2002)
  • [13] Candelario-Jalil E., Nimesulide as a promising neuroprotectant in brain ischemia: New experimental evidences, Pharmacol Res, 57, pp. 266-273, (2008)
  • [14] Candelario-Jalil E., Alvarez D., Merino N., Leon O.S., Delayed treatment with nimesulide reduces measures of oxidative stress following global ischemic brain injury in gerbils, Neurosci Res, 47, 2, pp. 245-253, (2003)
  • [15] Capone M.L., Tacconelli S., Di Francesco L., Sacchetti A., Sciulli M.G., Patrignani P., Pharmacodynamic of cyclooxygenase inhibitors in humans, Prostaglandins Other Lipid Mediat, 82, 1-4, pp. 85-94, (2007)
  • [16] Castillo J., Leira R., Moro M.A., Lizasoain I., Serena J., Davalos A., Neuroprotective effects of aspirin in patients with acute cerebral infarction, Neurosci Lett, 339, 3, pp. 248-250, (2003)
  • [17] Chae S.W., Kang B.Y., Hwang O., Choi H.J., Cyclooxygenase-2 is involved in oxidative damage and alpha-synuclein accumulation in dopaminergic cells, Neurosci Lett, 436, 2, pp. 205-209, (2008)
  • [18] Chaturvedi R.K., Beal M.F., PPAR: A therapeutic target in Parkinson's disease, J Neurochem, 106, 2, pp. 506-518, (2008)
  • [19] Chen Q., Olney J.W., Lukasiewicz P.D., Almli T., Romano C., Fenamates protect neurons against ischemic and excitotoxic injury in chick embryo retina, Neurosci Lett, 242, 3, pp. 163-166, (1998)
  • [20] Chen H., Jacobs E., Schwarzschild M.A., McCullough M.L., Calle E.E., Thun M.J., Ascherio A., Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease, Ann Neurol, 58, 6, pp. 963-967, (2005)
123456789